IMDX · Insight Molecular Diagnostics Inc.
$3.59
+0.15 (+4.36%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 10, 2026
The latest filing states the doubt was alleviated.
“Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that the consolidated financial statements are issued. ... Management has concluded that it is probable that our plans will be effectively implemented and that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date of issuance of these consolidated financial statements. ... Accordingly, management has concluded that substantial doubt does not exist about the Company's ability to continue as a going concern for a period of at least one year from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 10, 2026
Market Cap
$128.28M
Shares
32.72M
Volume · Oct 5
239.01K
Avg daily vol (3M)
232.26K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.44
Open$3.49
Day$3.36–3.60
52W close$2.55–8.48
Avg vol 30d241K
Short int992K · 3.0% float · 4.8d
Short vol39%
Last earningsAug 10, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 8, 2026
Est · unconfirmed
· in 5 wks
filed Aug 10, 2026
call held May 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.67M
Trailing 12 months
Net income (TTM)
−$49.36M
Trailing 12 months
Revenue growth YoY
-53.9%
Year over year
Operating margin
-3,011.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-24.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.8%
Year over year · more shares
Price change (1Y)
+3.0%
Trailing year
Short interest
3.0%
Latest settlement · 4.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−18%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
15%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−17%
trailing
6-month return
+15%
trailing
YTD return
−54%
this year
Relative strength
+2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.03% of float · ▲ +6.6% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
40 holders — near 3-yr high, broad support
Squeeze score
51
elevated · 0–100
Fundamentals
EPS growth
+65%
Y/Y
Free cash flow
$-25.4M
Balance sheet
$5.7M
net cash
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
10.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Nov 9, 2023
Cash burn
· quarterly basis
up to $5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−18%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
15%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-2% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.03% of float · ▲ +6.6% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
40 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $3 · 15%
Range high $8
vs 200-day avg -32%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA Loss non-GAAP | $7.8M | Q2 2026 | — |
| Adjusted EBITDA loss, a non-GAAP financial measure non-GAAP | -7.79M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Non-GAAP net loss -8.32M
+665K Depreciation and amortization expenses
+20K Interest expense
-162K Other income, net
+0K Income taxes
= Adjusted EBITDA loss, a non-GAAP financial measure -7.79M
|
|||
| free cash flow | $10M | Q2 2026 | — |
| non-GAAP operating expenses sequential change non-GAAP | 13% | Q2 2026 | — |
| non-GAAP operating expenses year-over-year change non-GAAP | 26% | Q2 2026 | — |
| pro-forma fully diluted share count | 36.9M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMDX
this stock
Insight Molecular Diagnostics Inc.
|
$128.28M | -54.1% | +115.6% | — | 3.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +13.0% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$150.37B | -6.5% | +8.5% | 37.9 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +79.1% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +23.3% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMDX | -12.2% | -16.5% | +14.7% | -4.2% | -54.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -12.0% | -16.0% | +2.5% | -5.1% | -67.0% |